Intratracheal poly (ADP) ribose synthetase inhibition ameliorates lung ischemia reperfusion injury

Alexander S. Farivar, Steven M. Woolley, Charles H. Fraga, Robert Thomas, Andrew L. Salzman, Csaba Szabo, Michael S. Mulligan

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background We previously demonstrated that intravenous poly (ADP) ribose synthetase (PARS) inhibition protects against experimental lung ischemia reperfusion injury (LIRI) in an in situ, hilar occlusion model. This study determined its efficacy when administered intratracheally (IT). Methods Left lungs of rats were rendered ischemic for 90 minutes, and reperfused for up to 4 hours. Treated animals received INO-1001, a PARS inhibitor, intratracheally 30 minutes before ischemia, while controls were given IT vehicle at equivalent volumes. All groups contained at least 4 animals. Lung injury was quantitated utilizing vascular permeability to radiolabeled albumin, tissue myeloperoxidase (MPO) content, alveolar leukocyte cell counts, and arterial pO2 at 4 hours of reperfusion. Electrophoretic mobility shift assays (EMSA) assessed the nuclear translocation of NFκB and AP-1 in injured left lungs, while ELISAs quantitated secreted cytokine induced neutrophil chemoattractant (CINC) and MCP-1 protein in bronchoalveolar lavage fluid. Results Intratracheal PARS inhibition was 73% (p < 0.0001) and 87% (p < 0.0001) protective against increases in vascular permeability and alveolar leukocyte accumulation, respectively, and improved arterial pO2 (p < 0.0004) at 4 hours of reperfusion. Myeloperoxidase (MPO) activity in treated lungs was reduced by 70% (p < 0.02). The nuclear translocation of NFκB and AP-1 was attenuated at 15 minutes of reperfusion, and the secretion of CINC and MCP-1 (p < 0.05) protein into the alveolus was diminished at 4 hours of reperfusion. Conclusions Intratracheal INO-1001 protects against experimental LIRI. The reduction in secreted chemokine protein at 4 hours of reperfusion appears to be mediated at the pretranscriptional level through attenuated NFκB and AP-1 activation. This route may optimize future donor organ management and improve lung recipient outcomes.

Original languageEnglish (US)
Pages (from-to)1938-1943
Number of pages6
JournalAnnals of Thoracic Surgery
Volume77
Issue number6
DOIs
StatePublished - Jun 2004
Externally publishedYes

Fingerprint

Poly Adenosine Diphosphate Ribose
Ligases
Reperfusion Injury
Reperfusion
Lung
Transcription Factor AP-1
Chemotactic Factors
Capillary Permeability
Peroxidase
Neutrophils
Cytokines
Alveolar Epithelial Cells
Proteins
Bronchoalveolar Lavage Fluid
Lung Injury
Electrophoretic Mobility Shift Assay
Leukocyte Count
Chemokines
Albumins
Leukocytes

Keywords

  • 12

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Farivar, A. S., Woolley, S. M., Fraga, C. H., Thomas, R., Salzman, A. L., Szabo, C., & Mulligan, M. S. (2004). Intratracheal poly (ADP) ribose synthetase inhibition ameliorates lung ischemia reperfusion injury. Annals of Thoracic Surgery, 77(6), 1938-1943. https://doi.org/10.1016/j.athoracsur.2003.10.120

Intratracheal poly (ADP) ribose synthetase inhibition ameliorates lung ischemia reperfusion injury. / Farivar, Alexander S.; Woolley, Steven M.; Fraga, Charles H.; Thomas, Robert; Salzman, Andrew L.; Szabo, Csaba; Mulligan, Michael S.

In: Annals of Thoracic Surgery, Vol. 77, No. 6, 06.2004, p. 1938-1943.

Research output: Contribution to journalArticle

Farivar, Alexander S. ; Woolley, Steven M. ; Fraga, Charles H. ; Thomas, Robert ; Salzman, Andrew L. ; Szabo, Csaba ; Mulligan, Michael S. / Intratracheal poly (ADP) ribose synthetase inhibition ameliorates lung ischemia reperfusion injury. In: Annals of Thoracic Surgery. 2004 ; Vol. 77, No. 6. pp. 1938-1943.
@article{96644c470f3442b59cba4ee7250a6eac,
title = "Intratracheal poly (ADP) ribose synthetase inhibition ameliorates lung ischemia reperfusion injury",
abstract = "Background We previously demonstrated that intravenous poly (ADP) ribose synthetase (PARS) inhibition protects against experimental lung ischemia reperfusion injury (LIRI) in an in situ, hilar occlusion model. This study determined its efficacy when administered intratracheally (IT). Methods Left lungs of rats were rendered ischemic for 90 minutes, and reperfused for up to 4 hours. Treated animals received INO-1001, a PARS inhibitor, intratracheally 30 minutes before ischemia, while controls were given IT vehicle at equivalent volumes. All groups contained at least 4 animals. Lung injury was quantitated utilizing vascular permeability to radiolabeled albumin, tissue myeloperoxidase (MPO) content, alveolar leukocyte cell counts, and arterial pO2 at 4 hours of reperfusion. Electrophoretic mobility shift assays (EMSA) assessed the nuclear translocation of NFκB and AP-1 in injured left lungs, while ELISAs quantitated secreted cytokine induced neutrophil chemoattractant (CINC) and MCP-1 protein in bronchoalveolar lavage fluid. Results Intratracheal PARS inhibition was 73{\%} (p < 0.0001) and 87{\%} (p < 0.0001) protective against increases in vascular permeability and alveolar leukocyte accumulation, respectively, and improved arterial pO2 (p < 0.0004) at 4 hours of reperfusion. Myeloperoxidase (MPO) activity in treated lungs was reduced by 70{\%} (p < 0.02). The nuclear translocation of NFκB and AP-1 was attenuated at 15 minutes of reperfusion, and the secretion of CINC and MCP-1 (p < 0.05) protein into the alveolus was diminished at 4 hours of reperfusion. Conclusions Intratracheal INO-1001 protects against experimental LIRI. The reduction in secreted chemokine protein at 4 hours of reperfusion appears to be mediated at the pretranscriptional level through attenuated NFκB and AP-1 activation. This route may optimize future donor organ management and improve lung recipient outcomes.",
keywords = "12",
author = "Farivar, {Alexander S.} and Woolley, {Steven M.} and Fraga, {Charles H.} and Robert Thomas and Salzman, {Andrew L.} and Csaba Szabo and Mulligan, {Michael S.}",
year = "2004",
month = "6",
doi = "10.1016/j.athoracsur.2003.10.120",
language = "English (US)",
volume = "77",
pages = "1938--1943",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Intratracheal poly (ADP) ribose synthetase inhibition ameliorates lung ischemia reperfusion injury

AU - Farivar, Alexander S.

AU - Woolley, Steven M.

AU - Fraga, Charles H.

AU - Thomas, Robert

AU - Salzman, Andrew L.

AU - Szabo, Csaba

AU - Mulligan, Michael S.

PY - 2004/6

Y1 - 2004/6

N2 - Background We previously demonstrated that intravenous poly (ADP) ribose synthetase (PARS) inhibition protects against experimental lung ischemia reperfusion injury (LIRI) in an in situ, hilar occlusion model. This study determined its efficacy when administered intratracheally (IT). Methods Left lungs of rats were rendered ischemic for 90 minutes, and reperfused for up to 4 hours. Treated animals received INO-1001, a PARS inhibitor, intratracheally 30 minutes before ischemia, while controls were given IT vehicle at equivalent volumes. All groups contained at least 4 animals. Lung injury was quantitated utilizing vascular permeability to radiolabeled albumin, tissue myeloperoxidase (MPO) content, alveolar leukocyte cell counts, and arterial pO2 at 4 hours of reperfusion. Electrophoretic mobility shift assays (EMSA) assessed the nuclear translocation of NFκB and AP-1 in injured left lungs, while ELISAs quantitated secreted cytokine induced neutrophil chemoattractant (CINC) and MCP-1 protein in bronchoalveolar lavage fluid. Results Intratracheal PARS inhibition was 73% (p < 0.0001) and 87% (p < 0.0001) protective against increases in vascular permeability and alveolar leukocyte accumulation, respectively, and improved arterial pO2 (p < 0.0004) at 4 hours of reperfusion. Myeloperoxidase (MPO) activity in treated lungs was reduced by 70% (p < 0.02). The nuclear translocation of NFκB and AP-1 was attenuated at 15 minutes of reperfusion, and the secretion of CINC and MCP-1 (p < 0.05) protein into the alveolus was diminished at 4 hours of reperfusion. Conclusions Intratracheal INO-1001 protects against experimental LIRI. The reduction in secreted chemokine protein at 4 hours of reperfusion appears to be mediated at the pretranscriptional level through attenuated NFκB and AP-1 activation. This route may optimize future donor organ management and improve lung recipient outcomes.

AB - Background We previously demonstrated that intravenous poly (ADP) ribose synthetase (PARS) inhibition protects against experimental lung ischemia reperfusion injury (LIRI) in an in situ, hilar occlusion model. This study determined its efficacy when administered intratracheally (IT). Methods Left lungs of rats were rendered ischemic for 90 minutes, and reperfused for up to 4 hours. Treated animals received INO-1001, a PARS inhibitor, intratracheally 30 minutes before ischemia, while controls were given IT vehicle at equivalent volumes. All groups contained at least 4 animals. Lung injury was quantitated utilizing vascular permeability to radiolabeled albumin, tissue myeloperoxidase (MPO) content, alveolar leukocyte cell counts, and arterial pO2 at 4 hours of reperfusion. Electrophoretic mobility shift assays (EMSA) assessed the nuclear translocation of NFκB and AP-1 in injured left lungs, while ELISAs quantitated secreted cytokine induced neutrophil chemoattractant (CINC) and MCP-1 protein in bronchoalveolar lavage fluid. Results Intratracheal PARS inhibition was 73% (p < 0.0001) and 87% (p < 0.0001) protective against increases in vascular permeability and alveolar leukocyte accumulation, respectively, and improved arterial pO2 (p < 0.0004) at 4 hours of reperfusion. Myeloperoxidase (MPO) activity in treated lungs was reduced by 70% (p < 0.02). The nuclear translocation of NFκB and AP-1 was attenuated at 15 minutes of reperfusion, and the secretion of CINC and MCP-1 (p < 0.05) protein into the alveolus was diminished at 4 hours of reperfusion. Conclusions Intratracheal INO-1001 protects against experimental LIRI. The reduction in secreted chemokine protein at 4 hours of reperfusion appears to be mediated at the pretranscriptional level through attenuated NFκB and AP-1 activation. This route may optimize future donor organ management and improve lung recipient outcomes.

KW - 12

UR - http://www.scopus.com/inward/record.url?scp=2542446153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542446153&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2003.10.120

DO - 10.1016/j.athoracsur.2003.10.120

M3 - Article

C2 - 15172241

AN - SCOPUS:2542446153

VL - 77

SP - 1938

EP - 1943

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 6

ER -